An Open Label, Phase 1 Study evaluating pharmacokinetics, safety and tolerability of ABT-869 in Subjects with Solid tumors
Phase 1
- Conditions
- solid tumors
- Registration Number
- JPRN-jRCT2080220594
- Lead Sponsor
- Abbott Japan Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Subjects aged from 20 to 75 years at date of consent.
2. Subject must have a solid tumor that is refractory to standard therapies or for which a standard effective therapy does not exist.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pharmacokinetics, safety and tolerability
- Secondary Outcome Measures
Name Time Method